Discrepancy of fasting plasma glucagon levels measured by different glucagon antisera. 1988

Y Tahara, and A Tanaka, and Y Yamamoto, and M Fukuda, and Y Kumahara, and K Shima
Department of Medicine and Geriatrics, Osaka University Medical School, Japan.

To investigate the possible discrepancy between immunoreactive glucagon (IRG) levels measured by two glucagon-specific antisera, OAL-123 and 30K, fasting plasma IRG levels were measured in 30 diabetics (DM group), 56 patients with impaired glucose tolerance (IGT group) and 96 normal subjects (normal group). The fasting plasma IRG measured by OAL-123 (OAL-IRG) in DM, IGT and normal groups were 121 +/- 53, 125 +/- 43 and 119 +/- 57 pg/ml, whereas the fasting plasma IRG measured by 30K (30K-IRG) were 109 +/- 92, 92 +/- 44 and 91 +/- 68 pg/ml, respectively. There was no significant difference in the distribution of the fasting IRG levels among DM, IGT and normal groups. Although there was a statistically significant correlation between OAL- and 30K-IRG, their correlation coefficient was as small as 0.29, and 31 of 182 cases showed a large discrepancy exceeding 100 pg/ml between the two IRG values. The OAL- and 30K-IRG measured again six months later did not show a significant change, where the first and second IRG levels showed a good correlation (0.72 and 0.83 for OAL- and 30K-IRG, both p less than 0.001). The gel chromatography of the 14 plasma with fasting OAL-IRG higher than 200 pg/ml showed that the main contributor to the fasting IRG was the component of big plasma glucagon (BPG). These data suggest that there is a significant discrepancy in the fasting plasma IRG levels measured by the different glucagon antisera and that the discrepancy is caused by the different immunoreactivity of BPG to the different glucagon antisera.

UI MeSH Term Description Entries
D007106 Immune Sera Serum that contains antibodies. It is obtained from an animal that has been immunized either by ANTIGEN injection or infection with microorganisms containing the antigen. Antisera,Immune Serums,Sera, Immune,Serums, Immune
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D005215 Fasting Abstaining from FOOD. Hunger Strike,Hunger Strikes,Strike, Hunger,Strikes, Hunger
D005934 Glucagon A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511) Glucagon (1-29),Glukagon,HG-Factor,Hyperglycemic-Glycogenolytic Factor,Proglucagon (33-61),HG Factor,Hyperglycemic Glycogenolytic Factor
D005951 Glucose Tolerance Test A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg). Intravenous Glucose Tolerance,Intravenous Glucose Tolerance Test,OGTT,Oral Glucose Tolerance,Oral Glucose Tolerance Test,Glucose Tolerance Tests,Glucose Tolerance, Oral
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Y Tahara, and A Tanaka, and Y Yamamoto, and M Fukuda, and Y Kumahara, and K Shima
May 1984, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology,
Y Tahara, and A Tanaka, and Y Yamamoto, and M Fukuda, and Y Kumahara, and K Shima
September 1983, Regulatory peptides,
Y Tahara, and A Tanaka, and Y Yamamoto, and M Fukuda, and Y Kumahara, and K Shima
December 2005, Endocrine journal,
Y Tahara, and A Tanaka, and Y Yamamoto, and M Fukuda, and Y Kumahara, and K Shima
September 1986, General and comparative endocrinology,
Y Tahara, and A Tanaka, and Y Yamamoto, and M Fukuda, and Y Kumahara, and K Shima
November 1984, Scandinavian journal of gastroenterology,
Y Tahara, and A Tanaka, and Y Yamamoto, and M Fukuda, and Y Kumahara, and K Shima
June 1991, Fish physiology and biochemistry,
Y Tahara, and A Tanaka, and Y Yamamoto, and M Fukuda, and Y Kumahara, and K Shima
November 1975, The Journal of clinical investigation,
Y Tahara, and A Tanaka, and Y Yamamoto, and M Fukuda, and Y Kumahara, and K Shima
November 1976, The American journal of physiology,
Y Tahara, and A Tanaka, and Y Yamamoto, and M Fukuda, and Y Kumahara, and K Shima
January 1987, Scandinavian journal of gastroenterology. Supplement,
Y Tahara, and A Tanaka, and Y Yamamoto, and M Fukuda, and Y Kumahara, and K Shima
December 1970, The Journal of clinical investigation,
Copied contents to your clipboard!